奥马珠单抗治疗一线治疗抵抗的大疱性类天疱疮:法国多中心回顾性100例研究
法国18个专家科室2014-2021年纳入100例一线治疗失败后使用奥马珠单抗的大疱性类天疱疮患者,完全缓解率77%,部分缓解9%,中位完全缓解时间3个月,复发率14%,不良事件4例。基线抗BP180-NC16A IgE升高者完全缓解率更高(75% vs 41%,P=0.011)。
要点
- 奥马珠单抗治疗一线抵抗的大疱性类天疱疮完全缓解率77%,部分缓解9%。
- 基线抗BP180-NC16A IgE升高者完全缓解率更高(75% vs 41%,P=0.011)。
- 剂量>300 mg每4周者疾病控制与完全缓解均显著快于≤300 mg每4周者。
核心结论
- 奥马珠单抗在一线治疗抵抗的大疱性类天疱疮中有效且安全,基线抗BP180-NC16A IgE可能预测治疗反应。
研究设计与样本
- 法国全国多中心回顾性研究,纳入2014-2021年18个专家科室的100例确诊大疱性类天疱疮患者,均在一线或多线治疗失败后接受奥马珠单抗。
主要发现
- 完全缓解率77%,部分缓解率9%;完全缓解维持情况:停药11.7%、最小治疗57.1%、非最小治疗31.2%。
- 中位完全缓解时间3个月(范围2.2-24.5),中位随访12个月(范围6-73)时复发率14%。
- 不良事件4例。
- 基线抗BP180-NC16A IgE升高者完全缓解率75% vs 41%(P=0.011);荨麻疹样皮损、血总IgE浓度或嗜酸性粒细胞计数不能预测完全缓解。
- 奥马珠单抗剂量>300 mg每4周 vs ≤300 mg每4周:最终结局相似,但疾病活动控制中位时间10天(范围5-30) vs 15天(范围10-60)(P<0.001),完全缓解中位时间2.4个月(范围2.2-8.2) vs 3.9个月(范围2.3-24.5)(P<0.001)。
关键数值与推荐
- 临床反应标准依据2012年国际共识会议定义。
- 排除临床非典型大疱性类天疱疮患者(依据Vaillant标准)。
临床怎么用
- 对于一线治疗抵抗或禁忌的大疱性类天疱疮,奥马珠单抗可作为治疗选择。
- 基线抗BP180-NC16A IgE可能有助于预测奥马珠单抗治疗反应。
- 剂量>300 mg每4周可能更快控制疾病活动和达到完全缓解。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interest in the use of omalizumab to treat bullous pemphigoid (BP) in the event of resistance or contraindication to conventional therapies is currently based on limited evidence. OBJECTIVES: To assess the effectiveness and safety of omalizumab in BP and to identify predictive factors in response to treatment. METHODS: We conducted a French national multicentre retrospective study including patients with a confirmed diagnosis of BP treated with omalizumab after failure of one or several treatment lines. We excluded patients with clinically atypical BP, as per Vaillant's criteria. The criteria for clinical response to omalizumab were defined according to the 2012 international consensus conference. Anti-BP180-NC16A IgE enzyme-linked immunosorbent assay was performed on sera collected before initiating omalizumab, when available. RESULTS: Between 2014 and 2021, 100 patients treated in 18 expert departments were included. Median age at diagnosis was 77 years (range 20-98). Complete remission (CR) was achieved in 77% of patients, and partial remission in an additional 9%. CR was maintained 'off therapy' in 11.7%, 'on minimal therapy' in 57.1%, and 'on non-minimal therapy' in 31.2%. Median time to CR was 3 months (range 2.2-24.5). Relapse rate was 14%, with a median follow-up time of 12 months (range 6-73). Adverse events occurred in four patients. CR was more frequently observed in patients with an increased serum baseline level of anti-BP180-NC16A IgE (75% vs. 41%; P = 0.011). Conversely, urticarial lesions, blood total IgE concentration or eosinophil count were not predictive of CR. Patients with an omalizumab dosage > 300 mg every 4 weeks showed a similar final outcome to those with a dosage ≤ 300 mg every 4 weeks, but control of disease activity [median 10 days (range 5-30) vs. 15 days (range 10-60); P < 0.001] and CR [median 2.4 months (range 2.2-8.2) vs. 3.9 months (range 2.3-24.5); P < 0.001] were achieved significantly faster. CONCLUSIONS: We report the largest series to date of BP treated by omalizumab and confirm its effectiveness and safety in this indication. Serum baseline level of anti-BP180-NC16A IgE may predict response to treatment.
引用
- Chebani R, Lombart F, Chaby G, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol. 2024. PMID: 37792727. doi:10.1093/bjd/ljad369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。